The subgroup analysis revealed that CD47 overexpression was related to inferior OS rates according to country, cancer type, sample size, analysis type, and the method via which the HR value was obtained (i.e., reported or extracted; p < 0.05); in addition, a high expression level of CD47 was also a predictor of poor DFS, PFS, and RFS rates (p < 0.00001). This evidence concerns the gene CD47 and cancer.